Shobit Rastogi, MD
Ophthalmology · Mooresville, NCNPI 1720062763
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Aerie Pharmaceuticals, Inc. accounts for 68.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $12,057 and has fallen 93.3% since, to $808 in 2025. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $147.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$23K
- Ivantis, Inc$3K
- Bausch & Lomb Americas Inc.$2K
- NEW World Medical,inc.$2K
- Alcon$1K
- AbbVie$1K
- plus $1K from 18 others
What the payments were for
- Consulting fees$2,3007%
- Speaking & faculty fees$20,35260%
- Travel & lodging$2,6318%
- Food & beverage$8,84126%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 54 | $23,494 |
| Ivantis, Inc | 14 | $2,834 |
| Bausch & Lomb Americas Inc. | 21 | $2,099 |
| NEW World Medical,inc. | 15 | $1,803 |
| Alcon | 33 | $1,262 |
| AbbVie(2 entities) | 41 | $1,160 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $284 |
| Sight Sciences, Inc. | 8 | $264 |
| Novartis | 8 | $172 |
| Amgen(2 entities) | 6 | $133 |
| Sun Pharmaceutical Industries Inc. | 5 | $111 |
| Biotissue Holdings Inc. | 3 | $90 |
| Kala Pharmaceuticals, Inc. | 3 | $63 |
| Optinose US, Inc. | 3 | $61 |
| Harrow Eye, LLC | 1 | $55 |
| Eyevance Pharmaceuticals LLC | 2 | $51 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Stryker | 1 | $16 |
| Akorn Operating Company LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$22,558
- Rhopressa$17,775
- Hydrus Microstent$2,000
- enVista Aspire IOL$1,394
- TENEO$1,394
- STELLARIS ELITE$1,394
- Ahmed Glaucoma Valve$1,384
- Kahook Dual Blade$1,384
- Streamline Surgical System$726
- Hydrus$503
- XEN GLAUCOMA TREATMENT SYSTEM$232
- Clareon$135
- RESTASIS$125
- ENVISTA ENVY IOL$121
- Tecnis 1-piece IOL$117
- DURYSTA$113
How this compares
$34,144 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 63 | $38,685 |
| RhopressaNetarsudil Mesylate | 47 | $26,849 |
| Prednisolone Acetate | 390 | $21,944 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $11,265 |
| Alphagan PBrimonidine Tartrate | 21 | $10,421 |
| MoxifloxacinMoxifloxacin Hcl | 311 | $8,319 |
| Latanoprost | 391 | $6,066 |
| Brimonidine Tartrate | 71 | $4,207 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 244 | $3,543 |
| Diclofenac Sodium | 192 | $2,002 |
| Travoprost | 18 | $1,071 |
| Atropine Sulfate | 26 | $932 |
| Dorzolamide Hcl | 58 | $819 |
| Timolol Maleate | 51 | $636 |
| Acetazolamide ErAcetazolamide | 18 | $574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P | $1,160 | $49,10684 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $23,494 | $38,11368 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Mooresville
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
- Thomas MundorfCharlotte$220K
- Glenn JaffeDurham$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.